NANO
NANOBIOTIX
Stock Euronext / Paris – Stock Market Prices, News & Analysis
Nanobiotix is a French biopharmaceutical company specializing in nanotechnologies applied to oncology. It develops innovative treatments aimed at enhancing the efficacy of radiotherapy through nanoparticles that locally amplify the effects of radiation. Its lead candidate, NBTXR3, is in clinical development for several types of cancer. The company positions itself at the forefront of precision medicine and physical anti-cancer therapies.
NANOBIOTIX
NANO
Nanobiotix is a French biopharmaceutical company specializing in nanotechnologies applied to oncology. It develops innovative treatments aimed at enhancing the efficacy of radiotherapy through nanoparticles that locally amplify the effects of radiation. Its lead candidate, NBTXR3, is in clinical development for several types of cancer. The company positions itself at the forefront of precision medicine and physical anti-cancer therapies.
Price history of NANOBIOTIX
Price history of NANOBIOTIX
Performance & Momentum
Nanobiotix Joins CAC Mid 60 and SBF 120 on Euronext Paris
Nanobiotix recently joined the CAC Mid 60 and SBF 120 indices, enhancing its visibility on Euronext Paris. This inclusion reflects the stock's significant progress, having doubled in value over three months and rising nearly 500% annually. The company also secured $71 million in non-dilutive funding to support its oncology clinical development, partnering with renowned institutions such as MD Anderson and Johnson & Johnson. These advances strengthen its position and could boost investor interest over the medium to long term.
Strategic Analysis
NANOBIOTIX • 2026
Nanobiotix positions itself as an innovative player in nanomedicine applied to oncology, with a business model focused on the development of nanoparticles capable of significantly enhancing the effectiveness of radiotherapies. Its specialization in precision physical anti-cancer treatments provides it with a promising niche in a sector with a high demand for therapeutic innovation.
Strengths
- Clinical advancement of its main therapeutic candidate NBTXR3 across multiple cancer indications
- Unique technological expertise in medical nanotechnologies to locally amplify the effects of radiotherapy
- French positioning with increasing recognition in the field of precision medicine
Weaknesses
- High dependence on clinical trial results for commercial validation
- Still an early-stage model with a current lack of consolidated recurring revenues
Momentum
The momentum is very favorable, driven by strong and regular stock progress linked to the increasing recognition of clinical and commercial prospects. This dynamism supports an investment strategy aimed at medium-term disruptive potential, while remaining subject to the typical risks of biopharmaceutical development.
Similar stocks to NANOBIOTIX
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
